The Global Sepsis Diagnostics Market size is expected to reach $879.5 million by 2028, rising at a market growth of 8.3% CAGR during the forecast period.
Sepsis is a medical disorder that emerges as a result of the body's response to infections caused by bacteria, viruses, or fungus. The immune system produces various substances into the bloodstream in this situation, causing hyper inflammation and the production of blood clots. Multiple organ failures, rapid breathing, neurological dysfunction, low blood pressure, and a higher heart rate are all possible complications of sepsis. Molecular diagnosis, biomarkers, flow cytometry, immunoassays, microfluidics, and other processes are used to diagnose sepsis. Hospitals, pathology and reference laboratories, university academic researchers, and other institutions are all using these diagnostic tools.
In 2016, the Third International Sepsis Consensus Task Force determined the current criteria for clinical sepsis diagnosis, known as Sequential Organ Failure Assessment (SOFA). This scoring system detects cumulative organ dysfunction as a result of an infection-induced dysregulation of the host's immune system. Cardiovascular function, respiration, liver function, coagulation, central nervous system function, and renal function are all regarded in the SOFA score.
A point is given for each malfunctioning organ system, with a score of 2 points or higher indicating a definite sepsis diagnosis. A high SOFA score is linked to a higher than 10% hospital mortality risk. Quick SOFA (qSOFA) is a rapid alternative to SOFA that uses only a subset of the SOFA scoring criteria, such as abnormal mentation, systolic blood pressure under 100 mm Hg, and a breathing rate of 22 or more per minute. qSOFA does not necessitate laboratory testing and can be performed as many times as needed.
SOFA replaces the Systemic Inflammatory Response Syndrome (SIRS) criteria, which was created in 2001. SIRS scoring requires two or more of the following: a temperature of greater than 38°C or less than 36°C, a heart rate of greater than 90 beats per minute, a respiratory rate of greater than 20 beats per minute, or a white blood cell count of greater than 12,000/L or less than 4,000/L. When compared to SIRS and qSOFA, SOFA has higher predictive accuracy.
COVID-19 Impact
The COVID-19 pandemic had a marginally beneficial impact on sepsis diagnostics sales. The widespread of COVID-19 and the emergence of sepsis cases among COVID-19 patients are projected to boost the demand for quick diagnosis, speeding up the use of tools, reagents, and test kits for sepsis detection. COVID-19 infection is more likely to affect surgeons and patients undergoing a variety of procedures in hospitals. The bulk of sepsis diagnostics was halted, leading to a decrease in device-based treatments. People postponed health exams as a result of the pandemic's lockdowns, lowering the number of tests conducted and laboratory sales.
Market Growth Factors
A rise in the number of hospital-acquired illnesses
HAIs also characterized as nosocomial infections, a prominent cause of morbidity and mortality in hospitals across the world. The most common hospital-acquired illnesses include urinary tract infections, pneumonia, and sepsis (HAIs). HAIs can induce sepsis in immunocompromised people, the elderly, and people with medical conditions. According to the Centres for Disease Control and Prevention (CDC), sepsis affects at least 1.7 million adults in the United States each year, with about 270,000 deaths. An illness obtained at a medical facility, such as an inpatient setting or a skilled nursing care facility, is characterized as a healthcare-acquired infection (HAI). An HAI might come from anywhere, even a doctor's office or clinic. HAIs are known as nosocomial infections in the medical world. Infections acquired outside of a healthcare centre are known as community-acquired infections.
The rapidly growing Molecular Diagnostics market
Due to their ease of use and effectiveness in diagnostic procedures, molecular diagnostics has attracted a number of multinational companies and institutes. The gold standard for molecular diagnostic methods has been blood culture analysis for quick and precise infection profiling. Several firms are investing in point-of-care molecular diagnostics to improve patient management and early detection of bacterial and viral infections. For example, Immunexpress debuted a quick SeptiCyte, a one-hour molecular diagnostic test for sepsis, on Biocartis' Idylla platform in October 2020. This is one of the first completely integrated, immune response-based diagnostics to help clinicians diagnose sepsis.
Market Restraints Factors
High expense of automated diagnostic instruments
Companies are focusing on creating automated diagnostic instruments for identifying sepsis based on modern technologies such as molecular diagnostics. However, government hospitals and scientific research laboratories cannot acquire such systems due to budget constraints. Furthermore, it is becoming a key impediment to the expansion of the sepsis diagnostics market. In addition, the lowest intensity sepsis cohort population had the major burden of recurrence and total expenses. Sepsis cases that were not discovered until hospitalization, along with those with increasing severity, had a greater economic cost and death rate on a case-by-case basis.
Method Outlook
Based on Method, the market is segmented into Conventional and Automated. The automated segment witnessed a substantial revenue share in the Sepsis Diagnostics Market in 2021. The use of billing codes and the installation of predictable evaluation are based on agreement definitions that have been used in efforts to automate sepsis identification. Although billing codes are simple to extract and have a strong positive predictive value (PPV) for sepsis, they typically do not document the onset of sepsis and have low sensitivity when compared to clinician assessment. Changing medical practicing habits and reimbursement policies also have an impact on them. Consensus-based definitions have improved over time and across institutions, but they still rely on doctors to validate if organ dysfunction is attributable to sepsis, resulting in low PPV when automated.
Test Type Outlook
Based on Test Type, the market is segmented into Laboratory Tests and Point-of-Care Tests. The laboratory tests procured the highest revenue share in the Sepsis Diagnostics Market in 2021. This is mostly attributable to the fact that laboratory testing is more accurate than POC testing when it comes to identifying sepsis. Laboratory testing allows for a comprehensive examination of the pathogen and its medication resistance profile. In addition, routine lactate testing, which is a vague but valuable indication of sepsis, is done efficiently in laboratory settings. The public's and physicians' dependence on these labs has grown dramatically with the introduction of technologically advanced products.
Pathogen Outlook
Based on Pathogen, the market is segmented into Bacterial Sepsis, Fungal Sepsis, Viral Sepsis, and Others. The fungal sepsis recorded a substantial revenue share in the Sepsis Diagnostics Market in 2021. Fungi are responsible for about 15% of all infections, and invasive fungal infections are becoming a more common cause of sepsis, especially in critically ill patients. This disease are life-threatening illness that can occur anywhere in the body as a result of an infection. Severe instances of sepsis are frequently caused by infections that spread throughout the body and through the bloodstream.
Product Outlook
Based on Product, the market is segmented into Blood Culture Media, Assays & Reagents, Instruments, and Software. The software segment registered a substantial revenue share in the Sepsis Diagnostics Market in 2021. This rapid expansion of this segment can be ascribed to a rise in healthcare professionals' implementation of modern software platforms for better sepsis detection and management. For example, Guthrie, anintegrated health care system, used Wolters Kluwer's POC Advisor to diagnose and treat sepsis at four local hospitals in September 2019.
End-User Outlook
Based on End-User, the market is segmented into Hospitals & specialty clinics, Pathology & Reference Laboratories, and Research Laboratories & Academic Institutes. The hospitals and specialty clinics segment procured the highest revenue share in the Sepsis Diagnostics Market in 2021. The rising number of patients diagnosed with sepsis, and in-house hospital and clinics are undertaking a large number of blood culture tests to identify blood stream infections (BSIs caused by bacteria, fungi/yeast, or viruses) contribute to the increased growth of this segment.
Technology Outlook
Based on Technology, the market is segmented into Blood Culture, Immunoassays, Molecular Diagnostics, Flow Cytometry, Microfluidics, and Biomarkers. The blood culture segment garnered the largest revenue share in the Sepsis Diagnostics Market in 2021. One of the most significant investigations in the treatment of sepsis is blood culture. It enables the identification of the sepsis-causing bacterium, the selection of a relevant empirical and specific antibiotic, and the identification of the infection's focal location. All sepsis patients should have a blood culture taken. Sepsis is traditionally described as the presence of infection-induced systemic inflammatory response syndrome (SIRS). Moreover, the affordable pricing of microbiological techniques and the widespread usage of blood culture procedures for sepsis diagnosis also account for this proportion.
Regional Outlook
Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa. The North America segment acquired the highest revenue share in the Sepsis Diagnostics Market in 2021. The medical device market in North America is well-established. The presence of a well-developed healthcare system, widespread implementation of innovative sepsis diagnosing technologies between health personnel, a reducing number of surgical procedures, growing prevalence of healthcare-associated infections (HAIs), and adoption of advanced technologies of sepsis diagnostics are all key factors that drive the sepsis diagnostics market in North America.
The major strategies followed by the market participants are Acquisitions. Based on the Analysis presented in the Cardinal matrix; F. Hoffmann-La Roche Ltd. is the major forerunner in the Sepsis Diagnostics Market. Companies such as Thermo Fisher Scientific, Inc., Bruker Corporation and BioMerieux S.A. are some of the key innovators in the Market.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include BioMerieux S.A., F. Hoffmann-La Roche Ltd., Becton, Dickinson and Company, Abbott Laboratories, Thermo Fisher Scientific, Inc., DiaSorin S.p.A., Bruker Corporation, Siemens Healthineers AG, Danaher Corporation, and Quidel Corporation.
Recent strategies deployed in Sepsis Diagnostics Market
Partnerships, Collaborations and Agreements:
Jan-2022: Oncocyte Corporation signed a development and co-marketing agreement with Thermo Fisher Scientific, an American supplier of scientific instrumentation, reagents and consumables, and software services. This agreement aimed to distribute Vitro diagnostic evaluation on Thermo Fisher Scientific's Ion Torrent Genexus System. Additionally, Oncocyte would clinically approve Thermo Fisher's existing Oncomine complete Assay Plus on the Genexus System, paving the way toward IVD authorization for use in tumour mark and future resignation as a companion diagnostic.
Sep-2021: Thermo Fisher Scientific joined hands with AstraZeneca, a multinational pharmaceutical and biotechnology company. Together, the companies aimed to co-build NGS-based companion diagnostics to support AstraZeneca's expanding offering of address therapies. Additionally, Thermo Fisher would provide the expertise, technology, and capabilities to disperse CDx tests to local healthcare suppliers around our global markets, which would help in identifying more patients across the world who may asset from effective patient care and treatments.
Sep-2021: Siemens Healthineers joined hands with A1 Life Sciences, a pioneering biotechnology company. Together, the companies aimed to support global attempts to record variants of SARS-CoV-2, allowing Siemens Healthineers to provide a developing offering of PCR-based appraisal for the recognization of SARS-CoV-2 variants and mutations.
Apr-2021: DiaSorin came into a definitive merger agreement for DiaSorin to acquire Luminex Corporation. Under this acquisition DiaSorin would gain approach to Luminex's molecular diagnostics multiplexing technology and a offering that would reinforce its existing suite while expanding its presence in the U.S.
Mar-2021: Roche signed an agreement to acquire GenMark Diagnostics, a leading provider of multiplex molecular diagnostic solutions. Under the terms of the merger agreement, Roche would directly commence a tender provide to obtain all outstanding shares of GenMark's common stock. Additionally, GenMark would file a endorsement statement containing the united recommendation of the GenMark board that GenMark stockholders delicate shares to Roche.
Product Launches and Product Expansions:
Dec-2021: BD expanded the BD COR System by including a new MX instrument. This expansion aimed to assist proteomic molecular testing for contagious diseases. Additionally, the MX instrument is designed to prove BD MAX System molecular PCR technology platform, a medium-throughput system usually found in hospital labs, and BD aims to use the BD MAX System menu of contagious disease trail to generate assays that can be achieved in high-throughput central reference labs on the BD COR System
Jul-2020: Bruker Corporation introduced FluoroType SARS-CoV-2 along with next-generation 6-plex PCR. The medicine appraisal for the highly specific observation of the SARS-CoV-2 virus, which causes systemic and respiratory disease. Additionally, FluoroType SARS-CoV-2 plus estimation is CE-IVD characterised as per the European IVD Directive. Moreover, two clinical testings require almost ninety CV19 positive patients and over 100 CV19 negative individuals, this enhanced CV19 infection estimation showed 100% specificity and sensitivity.
Acquisitions and Merger:
Dec-2021: Thermo Fisher Scientific completed the acquisition of PPD, a global contract research organization. Under this acquisition, Thermo Fisher planned to deliver an entire offering of services around the clinical development spectrum, handling trial logistics, efficacy and healthcare outcome assessment, safety, comprising scientific discovery, along with the production and advancement of the therapeutics.
Dec-2021: Quidel Corporation completed the acquisition of Ortho Clinical Diagnostics Holdings, an in vitro diagnostics company. Under this acquisition, Ortho would assist concrete Quidel as a leader in the diagnostics companies, bringing together complementary products, innovative, services, and solutions that improve the health and well-being of patients around the world.
Sep-2021: Abbott took over Walk Vascular, a commercial-stage medical device enterprise. Through this acquisition, Walk Vascular would integrate within the vascular device portfolio and further propel Abbott's capabilities to deliver one-of-a-kind endovascular treatment solutions to enhance patient care.
Apr-2021: Siemens Healthineers took over Varian Medical Systems, an American radiation oncology treatments and software developer. With this acquisition, Siemens Healthineers has the most complete suite in the MedTech sector, which provides the enterprise with appreciable potential for value creation. Additionally, Siemens Healthineer's integrated approach would take the broad fight against cancer to a new level.
Jan-2021: Thermo Fisher Scientific completed the acquisition of Mesa Biotech, a molecular diagnostic company. Under this acquisition, Mesa Biotech's convenient quick PCR-based test would highly integral to the existing portfolio and would further assist to fulfil the constant demand for COVID-related checking while the company works to rapidly scale and advance point-of-care tests for other contagious diseases in the future.
Approvals and Trials:
Mar-2021: Thermo Fisher Scientific received FDA approval for the Applied Biosystems QuantStudio 5 Dx Real-Time PCR System. The PCR System would clarify abilities to workflow decrease steps to provide quality results in less than 30 minutes. Moreover, the PCR system has high sensitivity and precision as well as delivers up to six channels for multiplexing.
Sep-2020: Roche received FDA approval for Elecsys HIV Duo immunoassay. The approval enables a strong complete infectious diseases menu on the Cobas e 801 system and is a compelling step towards bringing integrative value to the U.S. market within the area of contagious diseases.
Scope of the Study
Market Segments covered in the Report:
By Method
By Test Type
- Laboratory Tests
- Point-of-Care Tests
By Pathogen
- Bacterial Sepsis
- Fungal Sepsis
- Viral Sepsis
- Others
By Product
- Blood Culture Media
- Assays & Reagents
- Instruments
- Software
By End-User
- Hospitals & specialty clinics
- Pathology & Reference Laboratories
- Research Laboratories & Academic Institutes
By Technology
- Blood Culture
- Immunoassays
- Molecular Diagnostics
- Flow Cytometry
- Microfluidics
- Biomarkers
By Geography
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
- LAMEA
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Companies Profiled
- BioMerieux S.A.
- F. Hoffmann-La Roche Ltd.
- Becton, Dickinson and Company
- Abbott Laboratories
- Thermo Fisher Scientific, Inc.
- DiaSorin S.p.A.
- Bruker Corporation
- Siemens Healthineers AG
- Danaher Corporation
- Quidel Corporation
Unique Offerings from KBV Research
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
- 1.1 Market Definition
- 1.2 Objectives
- 1.3 Market Scope
- 1.4 Segmentation
- 1.4.1 Global Sepsis Diagnostics Market, by Method
- 1.4.2 Global Sepsis Diagnostics Market, by Test Type
- 1.4.3 Global Sepsis Diagnostics Market, by Pathogen
- 1.4.4 Global Sepsis Diagnostics Market, by Product
- 1.4.5 Global Sepsis Diagnostics Market, by End-User
- 1.4.6 Global Sepsis Diagnostics Market, by Technology
- 1.4.7 Global Sepsis Diagnostics Market, by Geography
- 1.5 Methodology for the research
Chapter 2. Market Overview
- 2.1 Introduction
- 2.1.1 Overview
- 2.1.1.1 Market Composition and Scenario
- 2.2 Key Factors Impacting the Market
- 2.2.1 Market Drivers
- 2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
- 3.1 KBV Cardinal Matrix
- 3.2 Recent Industry Wide Strategic Developments
- 3.2.1 Partnerships, Collaborations and Agreements
- 3.2.2 Product Launches and Product Expansions
- 3.2.3 Acquisition and Mergers
- 3.2.4 Approvals and Trials
- 3.3 Top Winning Strategies
- 3.3.1 Key Leading Strategies: Percentage Distribution (2018-2022)
- 3.3.2 Key Strategic Move: (Acquisitions and Mergers: 2018, Jul - 2021, Dec) Leading Players
Chapter 4. Global Sepsis Diagnostics Market by Method
- 4.1 Global Conventional Market by Region
- 4.2 Global Automated Market by Region
Chapter 5. Global Sepsis Diagnostics Market by Test Type
- 5.1 Global Laboratory Tests Market by Region
- 5.2 Global Point-of-Care Tests Market by Region
Chapter 6. Global Sepsis Diagnostics Market by Pathogen
- 6.1 Global Bacterial Sepsis Market by Region
- 6.2 Global Fungal Sepsis Market by Region
- 6.3 Global Viral Sepsis Market by Region
- 6.4 Global Others Market by Region
Chapter 7. Global Sepsis Diagnostics Market by Product
- 7.1 Global Blood Culture Media Market by Region
- 7.2 Global Assays & Reagents Market by Region
- 7.3 Global Instruments Market by Region
- 7.4 Global Software Market by Region
Chapter 8. Global Sepsis Diagnostics Market by End-User
- 8.1 Global Hospitals & specialty clinics Market by Region
- 8.2 Global Pathology & Reference Laboratories Market by Region
- 8.3 Global Research Laboratories & Academic Institutes Market by Region
Chapter 9. Global Sepsis Diagnostics Market by Technology
- 9.1 Global Blood Culture Market by Region
- 9.2 Global Immunoassays Market by Region
- 9.3 Global Molecular Diagnostics Market by Region
- 9.4 Global Flow Cytometry Market by Region
- 9.5 Global Microfluidics Market by Region
- 9.6 Global Biomarkers Market by Region
Chapter 10. Global Sepsis Diagnostics Market by Region
- 10.1 North America Sepsis Diagnostics Market
- 10.1.1 North America Sepsis Diagnostics Market by Method
- 10.1.1.1 North America Conventional Market by Country
- 10.1.1.2 North America Automated Market by Country
- 10.1.2 North America Sepsis Diagnostics Market by Test Type
- 10.1.2.1 North America Laboratory Tests Market by Country
- 10.1.2.2 North America Point-of-Care Tests Market by Country
- 10.1.3 North America Sepsis Diagnostics Market by Pathogen
- 10.1.3.1 North America Bacterial Sepsis Market by Country
- 10.1.3.2 North America Fungal Sepsis Market by Country
- 10.1.3.3 North America Viral Sepsis Market by Country
- 10.1.3.4 North America Others Market by Country
- 10.1.4 North America Sepsis Diagnostics Market by Product
- 10.1.4.1 North America Blood Culture Media Market by Country
- 10.1.4.2 North America Assays & Reagents Market by Country
- 10.1.4.3 North America Instruments Market by Country
- 10.1.4.4 North America Software Market by Country
- 10.1.5 North America Sepsis Diagnostics Market by End-User
- 10.1.5.1 North America Hospitals & specialty clinics Market by Country
- 10.1.5.2 North America Pathology & Reference Laboratories Market by Country
- 10.1.5.3 North America Research Laboratories & Academic Institutes Market by Country
- 10.1.6 North America Sepsis Diagnostics Market by Technology
- 10.1.6.1 North America Blood Culture Market by Country
- 10.1.6.2 North America Immunoassays Market by Country
- 10.1.6.3 North America Molecular Diagnostics Market by Country
- 10.1.6.4 North America Flow Cytometry Market by Country
- 10.1.6.5 North America Microfluidics Market by Country
- 10.1.6.6 North America Biomarkers Market by Country
- 10.1.7 North America Sepsis Diagnostics Market by Country
- 10.1.7.1 US Sepsis Diagnostics Market
- 10.1.7.1.1 US Sepsis Diagnostics Market by Method
- 10.1.7.1.2 US Sepsis Diagnostics Market by Test Type
- 10.1.7.1.3 US Sepsis Diagnostics Market by Pathogen
- 10.1.7.1.4 US Sepsis Diagnostics Market by Product
- 10.1.7.1.5 US Sepsis Diagnostics Market by End-User
- 10.1.7.1.6 US Sepsis Diagnostics Market by Technology
- 10.1.7.2 Canada Sepsis Diagnostics Market
- 10.1.7.2.1 Canada Sepsis Diagnostics Market by Method
- 10.1.7.2.2 Canada Sepsis Diagnostics Market by Test Type
- 10.1.7.2.3 Canada Sepsis Diagnostics Market by Pathogen
- 10.1.7.2.4 Canada Sepsis Diagnostics Market by Product
- 10.1.7.2.5 Canada Sepsis Diagnostics Market by End-User
- 10.1.7.2.6 Canada Sepsis Diagnostics Market by Technology
- 10.1.7.3 Mexico Sepsis Diagnostics Market
- 10.1.7.3.1 Mexico Sepsis Diagnostics Market by Method
- 10.1.7.3.2 Mexico Sepsis Diagnostics Market by Test Type
- 10.1.7.3.3 Mexico Sepsis Diagnostics Market by Pathogen
- 10.1.7.3.4 Mexico Sepsis Diagnostics Market by Product
- 10.1.7.3.5 Mexico Sepsis Diagnostics Market by End-User
- 10.1.7.3.6 Mexico Sepsis Diagnostics Market by Technology
- 10.1.7.4 Rest of North America Sepsis Diagnostics Market
- 10.1.7.4.1 Rest of North America Sepsis Diagnostics Market by Method
- 10.1.7.4.2 Rest of North America Sepsis Diagnostics Market by Test Type
- 10.1.7.4.3 Rest of North America Sepsis Diagnostics Market by Pathogen
- 10.1.7.4.4 Rest of North America Sepsis Diagnostics Market by Product
- 10.1.7.4.5 Rest of North America Sepsis Diagnostics Market by End-User
- 10.1.7.4.6 Rest of North America Sepsis Diagnostics Market by Technology
- 10.2 Europe Sepsis Diagnostics Market
- 10.2.1 Europe Sepsis Diagnostics Market by Method
- 10.2.1.1 Europe Conventional Market by Country
- 10.2.1.2 Europe Automated Market by Country
- 10.2.2 Europe Sepsis Diagnostics Market by Test Type
- 10.2.2.1 Europe Laboratory Tests Market by Country
- 10.2.2.2 Europe Point-of-Care Tests Market by Country
- 10.2.3 Europe Sepsis Diagnostics Market by Pathogen
- 10.2.3.1 Europe Bacterial Sepsis Market by Country
- 10.2.3.2 Europe Fungal Sepsis Market by Country
- 10.2.3.3 Europe Viral Sepsis Market by Country
- 10.2.3.4 Europe Others Market by Country
- 10.2.4 Europe Sepsis Diagnostics Market by Product
- 10.2.4.1 Europe Blood Culture Media Market by Country
- 10.2.4.2 Europe Assays & Reagents Market by Country
- 10.2.4.3 Europe Instruments Market by Country
- 10.2.4.4 Europe Software Market by Country
- 10.2.5 Europe Sepsis Diagnostics Market by End-User
- 10.2.5.1 Europe Hospitals & specialty clinics Market by Country
- 10.2.5.2 Europe Pathology & Reference Laboratories Market by Country
- 10.2.5.3 Europe Research Laboratories & Academic Institutes Market by Country
- 10.2.6 Europe Sepsis Diagnostics Market by Technology
- 10.2.6.1 Europe Blood Culture Market by Country
- 10.2.6.2 Europe Immunoassays Market by Country
- 10.2.6.3 Europe Molecular Diagnostics Market by Country
- 10.2.6.4 Europe Flow Cytometry Market by Country
- 10.2.6.5 Europe Microfluidics Market by Country
- 10.2.6.6 Europe Biomarkers Market by Country
- 10.2.7 Europe Sepsis Diagnostics Market by Country
- 10.2.7.1 Germany Sepsis Diagnostics Market
- 10.2.7.1.1 Germany Sepsis Diagnostics Market by Method
- 10.2.7.1.2 Germany Sepsis Diagnostics Market by Test Type
- 10.2.7.1.3 Germany Sepsis Diagnostics Market by Pathogen
- 10.2.7.1.4 Germany Sepsis Diagnostics Market by Product
- 10.2.7.1.5 Germany Sepsis Diagnostics Market by End-User
- 10.2.7.1.6 Germany Sepsis Diagnostics Market by Technology
- 10.2.7.2 UK Sepsis Diagnostics Market
- 10.2.7.2.1 UK Sepsis Diagnostics Market by Method
- 10.2.7.2.2 UK Sepsis Diagnostics Market by Test Type
- 10.2.7.2.3 UK Sepsis Diagnostics Market by Pathogen
- 10.2.7.2.4 UK Sepsis Diagnostics Market by Product
- 10.2.7.2.5 UK Sepsis Diagnostics Market by End-User
- 10.2.7.2.6 UK Sepsis Diagnostics Market by Technology
- 10.2.7.3 France Sepsis Diagnostics Market
- 10.2.7.3.1 France Sepsis Diagnostics Market by Method
- 10.2.7.3.2 France Sepsis Diagnostics Market by Test Type
- 10.2.7.3.3 France Sepsis Diagnostics Market by Pathogen
- 10.2.7.3.4 France Sepsis Diagnostics Market by Product
- 10.2.7.3.5 France Sepsis Diagnostics Market by End-User
- 10.2.7.3.6 France Sepsis Diagnostics Market by Technology
- 10.2.7.4 Russia Sepsis Diagnostics Market
- 10.2.7.4.1 Russia Sepsis Diagnostics Market by Method
- 10.2.7.4.2 Russia Sepsis Diagnostics Market by Test Type
- 10.2.7.4.3 Russia Sepsis Diagnostics Market by Pathogen
- 10.2.7.4.4 Russia Sepsis Diagnostics Market by Product
- 10.2.7.4.5 Russia Sepsis Diagnostics Market by End-User
- 10.2.7.4.6 Russia Sepsis Diagnostics Market by Technology
- 10.2.7.5 Spain Sepsis Diagnostics Market
- 10.2.7.5.1 Spain Sepsis Diagnostics Market by Method
- 10.2.7.5.2 Spain Sepsis Diagnostics Market by Test Type
- 10.2.7.5.3 Spain Sepsis Diagnostics Market by Pathogen
- 10.2.7.5.4 Spain Sepsis Diagnostics Market by Product
- 10.2.7.5.5 Spain Sepsis Diagnostics Market by End-User
- 10.2.7.5.6 Spain Sepsis Diagnostics Market by Technology
- 10.2.7.6 Italy Sepsis Diagnostics Market
- 10.2.7.6.1 Italy Sepsis Diagnostics Market by Method
- 10.2.7.6.2 Italy Sepsis Diagnostics Market by Test Type
- 10.2.7.6.3 Italy Sepsis Diagnostics Market by Pathogen
- 10.2.7.6.4 Italy Sepsis Diagnostics Market by Product
- 10.2.7.6.5 Italy Sepsis Diagnostics Market by End-User
- 10.2.7.6.6 Italy Sepsis Diagnostics Market by Technology
- 10.2.7.7 Rest of Europe Sepsis Diagnostics Market
- 10.2.7.7.1 Rest of Europe Sepsis Diagnostics Market by Method
- 10.2.7.7.2 Rest of Europe Sepsis Diagnostics Market by Test Type
- 10.2.7.7.3 Rest of Europe Sepsis Diagnostics Market by Pathogen
- 10.2.7.7.4 Rest of Europe Sepsis Diagnostics Market by Product
- 10.2.7.7.5 Rest of Europe Sepsis Diagnostics Market by End-User
- 10.2.7.7.6 Rest of Europe Sepsis Diagnostics Market by Technology
- 10.3 Asia Pacific Sepsis Diagnostics Market
- 10.3.1 Asia Pacific Sepsis Diagnostics Market by Method
- 10.3.1.1 Asia Pacific Conventional Market by Country
- 10.3.1.2 Asia Pacific Automated Market by Country
- 10.3.2 Asia Pacific Sepsis Diagnostics Market by Test Type
- 10.3.2.1 Asia Pacific Laboratory Tests Market by Country
- 10.3.2.2 Asia Pacific Point-of-Care Tests Market by Country
- 10.3.3 Asia Pacific Sepsis Diagnostics Market by Pathogen
- 10.3.3.1 Asia Pacific Bacterial Sepsis Market by Country
- 10.3.3.2 Asia Pacific Fungal Sepsis Market by Country
- 10.3.3.3 Asia Pacific Viral Sepsis Market by Country
- 10.3.3.4 Asia Pacific Others Market by Country
- 10.3.4 Asia Pacific Sepsis Diagnostics Market by Product
- 10.3.4.1 Asia Pacific Blood Culture Media Market by Country
- 10.3.4.2 Asia Pacific Assays & Reagents Market by Country
- 10.3.4.3 Asia Pacific Instruments Market by Country
- 10.3.4.4 Asia Pacific Software Market by Country
- 10.3.5 Asia Pacific Sepsis Diagnostics Market by End-User
- 10.3.5.1 Asia Pacific Hospitals & specialty clinics Market by Country
- 10.3.5.2 Asia Pacific Pathology & Reference Laboratories Market by Country
- 10.3.5.3 Asia Pacific Research Laboratories & Academic Institutes Market by Country
- 10.3.6 Asia Pacific Sepsis Diagnostics Market by Technology
- 10.3.6.1 Asia Pacific Blood Culture Market by Country
- 10.3.6.2 Asia Pacific Immunoassays Market by Country
- 10.3.6.3 Asia Pacific Molecular Diagnostics Market by Country
- 10.3.6.4 Asia Pacific Flow Cytometry Market by Country
- 10.3.6.5 Asia Pacific Microfluidics Market by Country
- 10.3.6.6 Asia Pacific Biomarkers Market by Country
- 10.3.7 Asia Pacific Sepsis Diagnostics Market by Country
- 10.3.7.1 China Sepsis Diagnostics Market
- 10.3.7.1.1 China Sepsis Diagnostics Market by Method
- 10.3.7.1.2 China Sepsis Diagnostics Market by Test Type
- 10.3.7.1.3 China Sepsis Diagnostics Market by Pathogen
- 10.3.7.1.4 China Sepsis Diagnostics Market by Product
- 10.3.7.1.5 China Sepsis Diagnostics Market by End-User
- 10.3.7.1.6 China Sepsis Diagnostics Market by Technology
- 10.3.7.2 Japan Sepsis Diagnostics Market
- 10.3.7.2.1 Japan Sepsis Diagnostics Market by Method
- 10.3.7.2.2 Japan Sepsis Diagnostics Market by Test Type
- 10.3.7.2.3 Japan Sepsis Diagnostics Market by Pathogen
- 10.3.7.2.4 Japan Sepsis Diagnostics Market by Product
- 10.3.7.2.5 Japan Sepsis Diagnostics Market by End-User
- 10.3.7.2.6 Japan Sepsis Diagnostics Market by Technology
- 10.3.7.3 India Sepsis Diagnostics Market
- 10.3.7.3.1 India Sepsis Diagnostics Market by Method
- 10.3.7.3.2 India Sepsis Diagnostics Market by Test Type
- 10.3.7.3.3 India Sepsis Diagnostics Market by Pathogen
- 10.3.7.3.4 India Sepsis Diagnostics Market by Product
- 10.3.7.3.5 India Sepsis Diagnostics Market by End-User
- 10.3.7.3.6 India Sepsis Diagnostics Market by Technology
- 10.3.7.4 South Korea Sepsis Diagnostics Market
- 10.3.7.4.1 South Korea Sepsis Diagnostics Market by Method
- 10.3.7.4.2 South Korea Sepsis Diagnostics Market by Test Type
- 10.3.7.4.3 South Korea Sepsis Diagnostics Market by Pathogen
- 10.3.7.4.4 South Korea Sepsis Diagnostics Market by Product
- 10.3.7.4.5 South Korea Sepsis Diagnostics Market by End-User
- 10.3.7.4.6 South Korea Sepsis Diagnostics Market by Technology
- 10.3.7.5 Singapore Sepsis Diagnostics Market
- 10.3.7.5.1 Singapore Sepsis Diagnostics Market by Method
- 10.3.7.5.2 Singapore Sepsis Diagnostics Market by Test Type
- 10.3.7.5.3 Singapore Sepsis Diagnostics Market by Pathogen
- 10.3.7.5.4 Singapore Sepsis Diagnostics Market by Product
- 10.3.7.5.5 Singapore Sepsis Diagnostics Market by End-User
- 10.3.7.5.6 Singapore Sepsis Diagnostics Market by Technology
- 10.3.7.6 Malaysia Sepsis Diagnostics Market
- 10.3.7.6.1 Malaysia Sepsis Diagnostics Market by Method
- 10.3.7.6.2 Malaysia Sepsis Diagnostics Market by Test Type
- 10.3.7.6.3 Malaysia Sepsis Diagnostics Market by Pathogen
- 10.3.7.6.4 Malaysia Sepsis Diagnostics Market by Product
- 10.3.7.6.5 Malaysia Sepsis Diagnostics Market by End-User
- 10.3.7.6.6 Malaysia Sepsis Diagnostics Market by Technology
- 10.3.7.7 Rest of Asia Pacific Sepsis Diagnostics Market
- 10.3.7.7.1 Rest of Asia Pacific Sepsis Diagnostics Market
- 10.3.7.7.2 Rest of Asia Pacific Sepsis Diagnostics Market by Method
- 10.3.7.7.3 Rest of Asia Pacific Sepsis Diagnostics Market by Test Type
- 10.3.7.7.4 Rest of Asia Pacific Sepsis Diagnostics Market by Pathogen
- 10.3.7.7.5 Rest of Asia Pacific Sepsis Diagnostics Market by Product
- 10.3.7.7.6 Rest of Asia Pacific Sepsis Diagnostics Market by End-User
- 10.3.7.7.7 Rest of Asia Pacific Sepsis Diagnostics Market by Technology
- 10.4 LAMEA Sepsis Diagnostics Market
- 10.4.1 LAMEA Sepsis Diagnostics Market by Method
- 10.4.1.1 LAMEA Conventional Market by Country
- 10.4.1.2 LAMEA Automated Market by Country
- 10.4.2 LAMEA Sepsis Diagnostics Market by Test Type
- 10.4.2.1 LAMEA Laboratory Tests Market by Country
- 10.4.2.2 LAMEA Point-of-Care Tests Market by Country
- 10.4.3 LAMEA Sepsis Diagnostics Market by Pathogen
- 10.4.3.1 LAMEA Bacterial Sepsis Market by Country
- 10.4.3.2 LAMEA Fungal Sepsis Market by Country
- 10.4.3.3 LAMEA Viral Sepsis Market by Country
- 10.4.3.4 LAMEA Others Market by Country
- 10.4.4 LAMEA Sepsis Diagnostics Market by Product
- 10.4.4.1 LAMEA Blood Culture Media Market by Country
- 10.4.4.2 LAMEA Assays & Reagents Market by Country
- 10.4.4.3 LAMEA Instruments Market by Country
- 10.4.4.4 LAMEA Software Market by Country
- 10.4.5 LAMEA Sepsis Diagnostics Market by End-User
- 10.4.5.1 LAMEA Hospitals & specialty clinics Market by Country
- 10.4.5.2 LAMEA Pathology & Reference Laboratories Market by Country
- 10.4.5.3 LAMEA Research Laboratories & Academic Institutes Market by Country
- 10.4.6 LAMEA Sepsis Diagnostics Market by Technology
- 10.4.6.1 LAMEA Blood Culture Market by Country
- 10.4.6.2 LAMEA Immunoassays Market by Country
- 10.4.6.3 LAMEA Molecular Diagnostics Market by Country
- 10.4.6.4 LAMEA Flow Cytometry Market by Country
- 10.4.6.5 LAMEA Microfluidics Market by Country
- 10.4.6.6 LAMEA Biomarkers Market by Country
- 10.4.7 LAMEA Sepsis Diagnostics Market by Country
- 10.4.7.1 Brazil Sepsis Diagnostics Market
- 10.4.7.1.1 Brazil Sepsis Diagnostics Market by Method
- 10.4.7.1.2 Brazil Sepsis Diagnostics Market by Test Type
- 10.4.7.1.3 Brazil Sepsis Diagnostics Market by Pathogen
- 10.4.7.1.4 Brazil Sepsis Diagnostics Market by Product
- 10.4.7.1.5 Brazil Sepsis Diagnostics Market by End-User
- 10.4.7.1.6 Brazil Sepsis Diagnostics Market by Technology
- 10.4.7.2 Argentina Sepsis Diagnostics Market
- 10.4.7.2.1 Argentina Sepsis Diagnostics Market by Method
- 10.4.7.2.2 Argentina Sepsis Diagnostics Market by Test Type
- 10.4.7.2.3 Argentina Sepsis Diagnostics Market by Pathogen
- 10.4.7.2.4 Argentina Sepsis Diagnostics Market by Product
- 10.4.7.2.5 Argentina Sepsis Diagnostics Market by End-User
- 10.4.7.2.6 Argentina Sepsis Diagnostics Market by Technology
- 10.4.7.3 UAE Sepsis Diagnostics Market
- 10.4.7.3.1 UAE Sepsis Diagnostics Market by Method
- 10.4.7.3.2 UAE Sepsis Diagnostics Market by Test Type
- 10.4.7.3.3 UAE Sepsis Diagnostics Market by Pathogen
- 10.4.7.3.4 UAE Sepsis Diagnostics Market by Product
- 10.4.7.3.5 UAE Sepsis Diagnostics Market by End-User
- 10.4.7.3.6 UAE Sepsis Diagnostics Market by Technology
- 10.4.7.4 Saudi Arabia Sepsis Diagnostics Market
- 10.4.7.4.1 Saudi Arabia Sepsis Diagnostics Market by Method
- 10.4.7.4.2 Saudi Arabia Sepsis Diagnostics Market by Test Type
- 10.4.7.4.3 Saudi Arabia Sepsis Diagnostics Market by Pathogen
- 10.4.7.4.4 Saudi Arabia Sepsis Diagnostics Market by Product
- 10.4.7.4.5 Saudi Arabia Sepsis Diagnostics Market by End-User
- 10.4.7.4.6 Saudi Arabia Sepsis Diagnostics Market by Technology
- 10.4.7.5 South Africa Sepsis Diagnostics Market
- 10.4.7.5.1 South Africa Sepsis Diagnostics Market by Method
- 10.4.7.5.2 South Africa Sepsis Diagnostics Market by Test Type
- 10.4.7.5.3 South Africa Sepsis Diagnostics Market by Pathogen
- 10.4.7.5.4 South Africa Sepsis Diagnostics Market by Product
- 10.4.7.5.5 South Africa Sepsis Diagnostics Market by End-User
- 10.4.7.5.6 South Africa Sepsis Diagnostics Market by Technology
- 10.4.7.6 Nigeria Sepsis Diagnostics Market
- 10.4.7.6.1 Nigeria Sepsis Diagnostics Market by Method
- 10.4.7.6.2 Nigeria Sepsis Diagnostics Market by Test Type
- 10.4.7.6.3 Nigeria Sepsis Diagnostics Market by Pathogen
- 10.4.7.6.4 Nigeria Sepsis Diagnostics Market by Product
- 10.4.7.6.5 Nigeria Sepsis Diagnostics Market by End-User
- 10.4.7.6.6 Nigeria Sepsis Diagnostics Market by Technology
- 10.4.7.7 Rest of LAMEA Sepsis Diagnostics Market
- 10.4.7.7.1 Rest of LAMEA Sepsis Diagnostics Market by Method
- 10.4.7.7.2 Rest of LAMEA Sepsis Diagnostics Market by Test Type
- 10.4.7.7.3 Rest of LAMEA Sepsis Diagnostics Market by Pathogen
- 10.4.7.7.4 Rest of LAMEA Sepsis Diagnostics Market by Product
- 10.4.7.7.5 Rest of LAMEA Sepsis Diagnostics Market by End-User
- 10.4.7.7.6 Rest of LAMEA Sepsis Diagnostics Market by Technology
Chapter 11. Company Profiles
- 11.1 BioMerieux S.A.
- 11.1.1 Company Overview
- 11.1.2 Financial Analysis
- 11.1.3 Segmental and Regional Analysis
- 11.1.4 Research & Development Expenses
- 11.1.5 Recent strategies and developments:
- 11.1.5.1 Acquisition and Mergers:
- 11.2 F. Hoffmann-La Roche Ltd.
- 11.2.1 Company Overview
- 11.2.2 Financial Analysis
- 11.2.3 Segmental and Regional Analysis
- 11.2.4 Research & Development Expense
- 11.2.5 Recent strategies and developments:
- 11.2.5.1 Partnerships, Collaborations, and Agreements:
- 11.2.5.2 Approvals and Trials:
- 11.3 Becton, Dickinson and Company
- 11.3.1 Company Overview
- 11.3.2 Financial Analysis
- 11.3.3 Segmental and Regional Analysis
- 11.3.4 Research & Development Expense
- 11.3.5 Recent strategies and developments:
- 11.3.5.1 Product Launches and Product Expansions:
- 11.4 Abbott Laboratories
- 11.4.1 Company Overview
- 11.4.2 Financial Analysis
- 11.4.3 Segmental and Regional Analysis
- 11.4.4 Research & Development Expense
- 11.4.5 Recent strategies and developments:
- 11.4.5.1 Acquisition and Mergers:
- 11.5 Thermo Fisher Scientific, Inc.
- 11.5.1 Company Overview
- 11.5.2 Financial Analysis
- 11.5.3 Segmental and Regional Analysis
- 11.5.4 Research & Development Expense
- 11.5.5 Recent strategies and developments:
- 11.5.5.1 Partnerships, Collaborations, and Agreements:
- 11.5.5.2 Approvals and Trials:
- 11.5.5.3 Acquisition and Mergers:
- 11.5.6 SWOT Analysis
- 11.6 DiaSorin S.p.A. (Luminex Corporation)
- 11.6.1 Company Overview
- 11.6.2 Financial Analysis
- 11.6.3 Regional Analysis
- 11.6.4 Research & Development Expenses
- 11.6.5 Recent strategies and developments:
- 11.6.5.1 Acquisitions and Mergers:
- 11.7 Bruker Corporation
- 11.7.1 Company Overview
- 11.7.2 Financial Analysis
- 11.7.3 Segmental and Regional Analysis
- 11.7.4 Research & Development Expense
- 11.7.5 Recent strategies and developments:
- 11.7.5.1 Product Launches and Product Expansions:
- 11.7.5.2 Acquisition and Mergers:
- 11.8 Siemens Healthineers AG (Siemens AG)
- 11.8.1 Company Overview
- 11.8.2 Financial Analysis
- 11.8.3 Segmental and Regional Analysis
- 11.8.4 Research & Development Expenses
- 11.8.5 Recent strategies and developments:
- 11.8.5.1 Partnerships, Collaborations, and Agreements:
- 11.8.5.2 Acquisition and Mergers:
- 11.9 Danaher Corporation
- 11.9.1 Company Overview
- 11.9.2 Financial Analysis
- 11.9.3 Segmental and Regional Analysis
- 11.9.4 Research & Development Expense
- 11.10. Quidel Corporation
- 11.10.1 Company Overview
- 11.10.2 Financial Analysis
- 11.10.3 Regional Analysis
- 11.10.4 Research & Development Expense
- 11.10.5 Recent strategies and developments:
- 11.10.5.1 Acquisition and Mergers: